Free LLS Education Program: Clinical Trial or Standard Treatment?
The next free education program offered by the Leukemia & Lymphoma Society will focus on understanding treatment options for patients with blood cancers.
This is the latest free telephone/web education program designed for patients with blood cancers and their loved ones.
This program will take place at 1 p.m. EST time on March 18.
Session to answer questions on clinical trials
The speaker is John P. Leonard, MD, Associate Dean for Clinical Research at Weill Cornell Medical College in New York. Dr. Leonard will be available during a question-and-answer session to address any issues related to clinical trials and standard care, including:
- The role of clinical trials in blood cancer treatment
- How clinical trials are designed
- How to determine the best treatment option for you
- Talking to your healthcare team about treatment options
To register or for more information, follow this link.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
